In the CHD cohort, 17% of patients were under treatment with nucleoside/nucleotide analogs (NA) and had median HDV and HBV viremia underneath the detection limit (HDV RNA: 0–12,200 IU/mL; HBV DNA: 0–200 IU/mL); 43% of HDV patients had previously undergone treatment with IFN-α and had a median HDV viremia of 32,000 IU/mL (870–220,000) and a median HBV viremia of 70 (6–790) IU/ml; 40% were therapy naïve and had a median HDV viremia under the limit of detection (0–300 IU/mL) and a median HBV DNA load of 378 (35–3,490) IU/ml. The gene discussed is IFNA17; the disease is coronary artery disorder.